Beyond Guam: The cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases

Amyotrophic Lateral Sclerosis

Volumn 10, Issue SUPPL. 2, 2009, Pages 7-20

  Bradley, Walter G ^a   Mash, Deborah C ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

ALS Parkinson Dementia Complex; Amyotrophic lateral sclerosis (ALS); BMAA; Cyanobacteria; Guam

Indexed keywords

2 AMINO 3 METHYLAMINOPROPIONIC ACID; BRAIN PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CHRONIC TOXICITY; CONFERENCE PAPER; CYANOBACTERIUM; CYCAS; DEGENERATIVE DISEASE; DEMENTIA; FOOD CHAIN; GENETIC SUSCEPTIBILITY; HUMAN; HUNTINGTON CHOREA; NEUROTOXICITY; PACIFIC ISLANDER; PARKINSON DISEASE; PRIORITY JOURNAL;

AMINO ACIDS, DIAMINO; AMYOTROPHIC LATERAL SCLEROSIS; BACTERIAL TOXINS; CYANOBACTERIA; ECOSYSTEM; GUAM; HUMANS; MARINE TOXINS; MICROCYSTINS; NEURODEGENERATIVE DISEASES;

EID: 74549175646     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482960903286009     Document Type: Conference Paper

References (162)

1. Tandan R, Bradley WG. Amyotrophic Lateral Sclerosis, Part I: Clinical features, pathology and ethical issues in management, Ann Neurol 1985a;18(3):271-280.
2. Tandan R, Bradley WG. Amyotrophic Lateral Sclerosis, Part II: Etiopathogenesis. Ann Neurol 1985b;18(4):419-431.
3. Rowland LP. Six important themes in amyotrophic lateral sclerosis (ALS) research, 1999. J Neurol Sci. 2000;180:2-6.
4. Bradley WG. Collaborative National ALS Study Group. Patient orientated research and clinical trials. J Neurol Sci. 2006;242:71-4.
5. th edn, Butterworth, MA. 2008:2183-220.
6. Kuzuhara S. Revisit to Kii ALS-the innovated concept of ALS-Parkinsonism-dementia complex, clinicopathological features, epidemiology and etiology. Brain Nerve. 2007;59:1065-74.
7. Spencer PS, Palmer VS, Ludolph AC. On the decline and etiology of high-incidence motor system disease in West Papua (southwest New Guinea). Mov Disord. 2005;20 (Suppl 12):S119-26.
8. McConnell J. Cyanobacteria, cycads, Chiroptera, and the Chamorro. Lancet Inf Dis. 2004;4:391.
9. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/ Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59-62.
10. Beleza-Meireles A, Al-Chalabi A. Genetic studies of amyotrophic lateral sclerosis: controversies and perspectives. ALS. 2009;10:1-14.
11. Mitchell JD. Amyotrophic lateral sclerosis: toxins and environment. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Sep;1(4):235-50.
12. Prasad U, Kurland LT. Arrival of new diseases on Guam: lines of evidence suggesting the post-Spanish origins of ALS and Parkinson's dementia. Journal of Pacific History. 1997;32:217-28.
13. Zimmerman HM, quoted in (12).
14. Kurland LK, Mulder DW. Epidemiologic investigations of amyotrophic lateral sclerosis: I. Preliminary report on geographic distribution, with particular reference to the Mariana Islands, including clinical and pathologic observations. Neurology. 1954;4:355-378; 338-348.
15. Mulder DW, Kurland LT, Iriarte LL. Neurologic diseases on the island of Guam. US Armed Forces Me J. 1954;5: 1724-39.
16. Torres J, Iriarte LLG, Kurland LT. Amyotrophic lateral sclerosis among Guamanians in California. Calif Med. 1957;86(4):385-8.
17. Garruto RM, Gajdusek C, Chen KM. Amyotrophic lateral sclerosis among Chamorro migrants from Guam. Ann Neurol. 1980 Dec;8(6):612-9.
18. Garruto RM, Gajdusek DC, Chen KM. Amyotrophic lateral sclerosis and parkinsonism-dementia among Filipino migrants to Guam. Ann Neurol. 1981 Oct;10(4):341-50.
19. Whiting MG. 1962. Quoted in 86.
20. Mason MM, Whiting MG. Caudal motor weakness and ataxia in cattle in the Caribbean area following ingestion of cycads. Cornell Vet. 1968;48:541-54.
21. Reed D, Labarthe D, Chen KM, Stallones R. A cohort study of amyotrophic lateral sclerosis and parkinsonism-dementia on Guam and Rota. Am J Epidemiol. 1987;125(1):92-100.
22. Bell EA. Relevance of biochemical taxonomy to the problem of lathyrism. Nature. 1964 July 25;203:378-380.
23. Vega A, Bell EA. α-Amino-β-methylaminopropionic acid, a new amino acid from seeds of Cycas circinalis. Phytochemistry. 1967;6:759-62.
24. Spencer PS, Schaumburg HH. Lathyrism: a neurotoxic disease. Neurobehav Toxicol Teratol. 1983;5:625-9.
25. Spencer PS, Nunn PB, Hugon J, et al. Motorneurone disease on Guam: possible role of a food neurotoxin. Lancet. 1986a;i:965.
26. Spencer PS, Roy DN, Ludolph A, et al. Lathyrism: evidence for role of the neuroexcitatory aminoacid BOAA. Lancet. 1986b;ii:1066-7.
27. Spencer PS. Guam ALS/parkinsonism-dementia: a long-latency neurotoxic disorder caused by "slow toxin(s)" in food? Can J Neurol Sci. 1987;14(Suppl 3):347-57.
28. Spencer PS, Hugon J, Ludolph A, et al. Discovery and partial characterization of primate motor-system toxins. Ciba Found Symp. 1987;126:221-38.
29. Ross SM, Spencer PS. Specific antagonism of behavioral action of "uncommon" amino acids linked to motor-system diseases. Synapse. 1987;1:248-53.
30. Ross SM, Seelig M, Spencer PS. Specific antagonism of excitotoxic action of 'uncommon' amino acids assayed in organotypic mouse cortical cultures. Brain Res. 1987; 425:120-7.
31. Nunn PB, Seelig M, Zagoren JC, et al. Stereospecific acute neuronotoxicity of 'uncommon' plant amino acids linked to human motor-system diseases. Brain Res. 1987;410:375-9.
32. Spencer PS, Kisby GE, Ludolph AC. Long-latency neurodegenerative disease in the western Pacific. Geriatrics. 1991a; 46(Suppl 1):37-42.
33. Spencer PS, Kisby GE, Ludolph AC. Slow toxins, biologic markers, and long-latency neurodegenerative disease in the western Pacific region. Neurology. 1991b;41(Suppl 2):62-6.
34. Spencer PS, Allen RG, Kisby GE, Ludolph AC. Exitotoxic disorders. Science. Apr 13, 1990;248:144.
35. Rubinstein E. Biologic effects of and clinical disorders caused by nonprotein amino acids. Medicine. 2000;79(2): 80-89.
36. Duncan MW, Kopin IJ, Garruto RM, et al. 2-Amino-3(methylamino)-propionic acid in cycad-derived foods is an unlikely cause of amiyotrophic lateral sclerosis/parkinsonism. Lancet. 1988;ii:631-2.
37. Duncan MW, Steele JC, Kopin IJ, et al. 2-Amino-3-(methylamino)-propanoic acid (BMAA) in cycad flour:an unlikely cause of amyotrophic lateral sclerosis andparkinsonism-dementia of Guam. Neurology. 1990;40:767-72.
38. Duncan MW, Villacreses NE, Pearson PG, et al. 2-amino-3-(methylamino)- propanoic acid (BMAA) pharmacokinetics and blood-brain barrier permeability in the rat. J Pharmacol Exp Ther. 1991;258:27-35.
39. Smith QR, Nagura H, Takada Y, Duncan MW. Facilitated transport of the neurotoxin, β-N-methylamino-L-alanine, across the blood-brain barrier. J Neurochem. 1992;58: 1330-7.
40. Duncan MW. Beta methylamino-L-alanine (BNAA) and ALS/parkinsonism dementia of the western Pacific. Ann NY Acad Sc. 1992;648:161-8.
41. Maurizi CP. Was a neurovirulent influenza virus the cause of amyotrophic lateral sclerosis and parkinsonism-dementia on Guam? Med Hypotheses. 1987;23:325-6.
42. Reed DM, Brody JA. Amyotrophic lateral sclerosis and parkinsonism- dementia on Guam, 1945-1972. I. Descriptive epidemiology. Am J Epidemiol. 1975;101:287-301.
43. Perl DP, Gajdusek DC, Garruto RM, et al. Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam. Science. 1982;217:1053-5.
44. Perl DP, Moalem S. Aluminum and Alzheimer's disease, a personal perspective after 25 years. J Alzheimers Dis. 2006; 9(3 Suppl):291-300.
45. Cox PA, Sacks OW Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. Neurology. 2002;58:956-9.
46. Cox PA, Banack SA, Murch SJ. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc Natl Acad Sci USA. 2003;100:13380-3.
47. Banack SA, Cox PA. Biomagnification of cycad neurotoxins in flying foxes: implications for ALS-PDC in Guam. Neurology. 2003;61:387-9.
48. Murch SJ, Cox PA, Banack SA, Steele JC, Sacks OW. Occurrence of β-methylamino-l-alanine (BMAA) in ALS/PDC patients from Guam. Acta Neurol Scand. 2004a;110(4): 267-269.
49. Murch SJ, Cox PA, Banack SA. A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. Proceedings of the National Academy of Sciences. 2004b;101:12228-31.
50. Banack SA, Murch SJ, Cox PA. Neurotoxic flying foxes as dietary items for the Chamorro people, Marianas Islands. J Ethnopharmacol. 2006;106:97-104.
51. Banack SA, Johnson HE, Cheng R, Cox PA. Production of the Neurotoxin BMAA by a Marine Cyanobacterium. Mar Drugs. 2007 Dec 6;5(4):180-96.
52. Rao SD, Banack SA, Cox PA, et al. BMAA selectively injures motor neurons via AMPA/kainate receptor activation. Exp Neurol. 2006;201:244-52.
53. Cox PA, Banack SA, Murch SJ, Cyanobacteria, Cycads, and Neurodegenerative Disease among the Chamorro People of Guam. In: Vovides AP, Stevenson DW, Osborne R, editors. Proceedings of Cycad 2005: The 7th International Conference on Cycad Biology, New York: New York Botanical Garden Press. 2007;253-285.
54. Allende CC, Allende JE. Purification and substrate specificity of arginyl-ribonucleic acid synthetase from rat liver. J Biol Chem. 1964;239:1102-1106.
55. Polsky FI, Nunn PB, Bell EA. Distribution and toxicity of α-amino-β-methyl-aminopropionic acid. Fed Proc. 1972;31: 1473-1475.
56. Rodgers KJ, Shiozawa N. Misincorporation of amino acid analogues into proteins by biosynthesis. Int J Biochem Cell Bio. 2008;40:1452-1466.
57. Wilhelm SW. Ecology of iron-limited cyanobacteria: a review of physiological responses and implications for aquatic systems. Aquat microbial Ecol. 1995;9:295-303.
58. Usher KM, Bergman B, Raven JA. Exploring cyanobacterial mutualisms. Ann Rev Ecol Evol Systemat. 2007;38: 255-273.
59. Mash D, Pablo J, Banack SA, et al. Neurotoxic non-protein amino acid BMAA in brain from patients dying with ALS and Alzheimer's disease. American Academy of Neurology annual meeting. P06.127. Neurology. 2008; 70(Suppl 1): A329.
60. Pablo J, Banack SA, Cox PA, Johnson TE, Papapetropoulos S, Bradley WG, Buck A, Mash DC. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol Scand. 2009 Feb 25; DOI: 10.1111/j.1600-0404.2008. 01150.x.
61. Mash D, Pablo J et al. 2009, paper in preparation.
62. Valentino KM, Dugger NV, Peterson E, Wilson JM et al. Environmentally induced parkinsonism in cycad-fed rats. Society for Neuroscience Abstracts 2006;Poster 755.11/ CC19.
63. Karlsson O, Berg C, Brittebo EB, Lindquist NG. Retention of the cyanobacterial neurotoxin β-N-methylamino-L-alanine in melanin and melanin-containing cells - a possible link between Parkinson-dementia complex and pigmentary retinopathy. Pigment Cell Melanoma Res. 2008;22:120-30.
64. Santucci S, Zsürger N, Chabry J. β-N-methylamino-L-alanine induced in vivo retinal cell death. J Neurochem. 2009; 10.1111/j.1471-4159.2009. 06022.x.
65. Karlsson O, Lindquist NG, Brittebo EB, Roman E. Selective brain uptake and behavioral effects of the cyanobacterial toxin BMAA following neonatal administration to rodents. Toxicol Sci. 2009;109:286-295.
66. Cox PA, Banack SA, Murch SJ, et al. Diverse taxa of cyanobacteria produce β-N-methylamino-L-alanine, a neurotoxic amino acid. Proc Nat Acad Sci. 2005;102:5074-78.
67. Garcia-Pichel F, López-Cortés A, Nübel U Phylogenetic and morphological diversity of cyanobacteria in soil desert crusts from the Colorado plateau. Appl Environ Microbiol. 2001 Apr;67(4):1902-10.
68. Sompong U, Hawkins PR, Besley C, Peerapornpisal Y. The distribution of cyanobacteria across physical and chemical gradients in hot springs in northern Thailand. FEMS Mcrobiol Ecol. 2005 May 1;52(3):365-76.
69. Walker JJ, Pace NR. Endolithic microbial ecosystems. Annu Rev Microbiol. 2007;61:331-47.
70. Gorbushina AA. Life on the rocks. Environ Microbiol. 2007 Jul;9(7):1613-31.
71. Johnson HE, King SR, Banack SA, Webster C, Callanaupa WJ, Cox PA. Cyanobacteria (Nostoc commune) used as a dietary item in the Peruvian highlands produce the neurotoxic amino acid BMAA. J Ethnopharmacol. 2008 Jun 19;118(1): 159-65.
72. Metcalf JS, Banack SA, Lindsay J, et al. Co-occurrence of b-N-methylamino-L-alanine, a neurotoxic amino acid, with other cyanobacterial toxins in British waterbodies, 1990- 2004. Environmental Microbiology. 2008;10:702-708.
73. Jonasson S, Eriksson J, Berntzon L et al. A novel cyanobacterial toxin (BMAA) with potential neurodegenerative effects. Plant Biotech. 2008;25:227-32.
74. Plato CC, Garruto RM, Galasko D, Craig U-K et al. Amyotrophic lateral sclerosis and Parkinson-dementia complex of Guam: changing incidence rates during the past 60 years. Amer J Epidemiol. 2003;157:149-157.
75. Galasko D, Salmon D, Gamst A, Olichney J. Prevalence of dementia in Chamorros on Guam: relationship to age, gender, education, and APOE. Neurology. 2007 May 22; 68(21):1772-81. Comment: Neurolory. 2007 May 22; 68(21):1759-61.
76. Monson CS, Banack SA, Cox PA. Conservation implications of Chamorro consumption of flying foxes as a possible cause of ALS-PDC in Guam. Conservation Biol. 2003;17:678-86.
77. Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with intial penicillamine therapy. Arch Neurol. 1987;44:490-3.
78. Veen C, van den Hamer CJ, de Leeuw PW. Zinc sulphate therapy for Wilson's disease after acute deterioration during treatment with low-dose D-penicillamine. J Intern Med. 1991;229:549-552.
79. Lang CJ, Rabas-Kolominsky P, Engelhardt A, Kobras G, Konig HJ. Fatal deterioration of Wilson's disease after institution of oral zinc therapy. Arch Neurol. 1993;50:1007-8.
80. Gibberd FB, Billimoria JD, Page NG, Retsas S. Heredopathia atactica polyneuritiformis (Refsum's disease) treated by diet and plasma-exchange. Lancet. 1979;1(8116):575-8.
81. Harari D, Gibberd FB, Dick JP, Sidey MC. Plasma exchange in the treatment of Refsum's disease. J Neurol Neurosurg Psychiat. 1991;54:614-7.
82. Kuzuhara S, Kokubo Y. Atypical parkinsonism of Japan: amyotrophic lateral sclerosis-parkinsonism-dementia complex of the Kii peninsula of Japan (Muro disease): an update. Mov Disord. 2005 (Suppl 12):S108-13.
83. Ince PG, Codd GA. Return of the cycad hypothesis - does the amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) of Guam have new implications for global health? Neuropathol Appl Neurobiol. 2005;31:345-53.
84. Miller G. Guam's Deadly Stalker: On the Loose Worldwide? Science. 2006;313:428-431.
85. Papapetropoulos S. Is there a role for naturally occurring cyanobacterial toxins in neurodegeneration? The beta-N-methylamino-L-alanine (BMAA) paradigm. Neurochem Int. 2007;50:998-1003.
86. Karamyan VT, Speth RC. Animal models of BMAA neurotoxicity: a critical review. Life Sci. 2008;82:233-46.
87. Rothman SM, Olney JW. Excitotoxicity and the NMDA receptor--still lethal after eight years. Trends Neurosci. 1995;18:57-8.
88. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988;1:623-34.
89. 2+-permeable AMPA channel blocker slows loss of both motor neurons and of the astrocyte glutamate transporter, GLT-1 in a mutant SOD1 rat model of ALS. Exp Neurol. 2007;207: 177-85.
90. Rothstein JD, Dykes-Hoberg M, Pardo CA, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996;16:675-86.
91. Trotti D, Rolfs A, Danbolt NC, et al. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci. 1999;2:427-33.
92. Gredal O, Møller SE. Effect of branched-chain amino acids on glutamate metabolism in amyotrophic lateral sclerosis. J Neurol Sci. 1995;129:40-3.
93. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585-91.
94. Weiss JH, Christine CW, Choi DW. Bicarbonate dependence of glutamate receptor activation by ß-N-methylamino-L-alanine. Neuron. 1989a;3(3):321-6.
95. Weiss JH, Koh JY, Choi DW. Neurotoxicity of beta-N-methylamino-L-alanine (BMAA) and beta-N-oxalylamino-L-alanine (BOAA) on cultured cortical neurons. Brain Res. 1989b;497:64-71.
96. Rakonczay Z, Matsuoka Y, Giacobini E. Effects of L-beta-N-methylamino-L- alanine (L-BMAA) on the cortical cholinergic and glutamatergic systems of the rat. J Neurosci Res. 1991 May;29(1):121-6.
97. Matsuoka Y, Rakonczay Z, Giacobini E, Naritoku D. L-beta-methylamino- alanine-induced behavioral changes in rats. Pharmacol Biochem Behav. 1993 Mar;44(3):727-34.
98. Brownson DM, Mabry TJ, Leslie SW. The cycad neurotoxic amino acid, beta-N-methylamino-L-alanine (BMAA), elevates intracellular calcium levels in dissociated rat brain cells. J Ethnopharmacol. 2002;82:159-67.
99. Buenz EJ, Howe DL. Beta-methylamino-alanine (BMAA) injures hippocampal neurons in vivo. Neurotoxicology. 2007;28:702-4.
100. Spencer PS, Nunn PB, Hugon J, et al. Guam ALS-parkinsonism-dementia linked to a plant excitant neurotoxin. Science. 1987;237:517-22.
101. Cha JH, Makowiec RL, Penney JB, et al. L-[3H]-glutamate labels the metabotropic excitatory amino acid receptor in rodent brain. Neurosci Lett. 1990;113:78-83.
102. Copani A, Canonico PL, Catania MV, et al. Interaction between beta-N-methylamino-L-alanine and excitatory amino acid receptors in brain slices and neuronal cultures. Brain Res. 1991;558:79-86.
103. Staton PC, Bristow DR. The dietary excitotoxins beta-N-methylamino-L- alanine and beta-N-oxalylamino-L-alanine induce necrotic- and apoptotic-like death of rat cerebellar granule cells. J Neurochem. 1997;69:1508-18.
104. Nunn PB, Davis AJ, O'Brien P. Carbamate formation and the neurotoxicity of L-alpha amino acids. Science. 1991;251:1619-20.
105. Pai KS, Shankar SK, Ravindranath V. Billion-fold difference in the toxic potencies of two excitatory plant amino acids, L-BOAA and L-BMAA: biochemical and morphological studies using mouse brain slices. Neurosci Res. 1993; 17(3): 241-8.
106. Armstrong RA, Lantos PL, Cairns NJ. What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease? Neuropathology. April 23, 2008; 1-15.
107. Karunakaran S, Saeed U, Ramakrishnan S, Koumar RC, Ravindranath V. Constitutive expression and functional characterization of mitochondrial glutaredoxin (Grx2) in mouse and human brain. Brain Res. 2007 Dec. 14;1185: 8-17.
108. Saeed U, Durgadoss L, Valli RK, Joshi DC et al. Knockdown of cytosolic glutaredoxin-1 leads to loss of mitochondrial membrane potential: implication for neurodegenerative diseases. PLoS ONE. 2008;3(6):e2459.
109. Lobner D, Piana PM, Salous AK, et al. Beta-N-methyl-amino-L-alanine enhances neurotoxicity through multiple mechanisms. Neurobiol Dis. 2007;25:360-6.
110. Liu X, Rush T, Jasmine Z, Lobner D. Beta-N-methylamino-L-alanine induces oxidative stress and glutamate release through action on system Xc. Experimental Neurol. 2009; doi:10.1016/j.expneurol.2009.04.002.
111. Cyanosite at http://www-cyanosite.bio.purdue.edu/index. html (accessed July 14, 2009).
112. Stewart I, Seawright AA, Shaw GR. Cyanobacterial poisoning in livestock, wild animals and birds - an overview. Adv Exp Med Biol. 2008;619:613-37.
113. Nunn PB, Ponnusamy M. β-N-Methylaminoalanine (BMAA): Metabolism and metabolic effects in model systems and in neural and other tissues of the rat in vitro. Toxicon. 2009;54:85-94.
114. Eriksson J, Jonasson S, Papaefthimiou D, Rasmussen U, Bergman B. Improving derivatization efficiency of BMAA utilizing AccQ-Tag® in a complex cyanobacterial matrix. Amino Acids. 2009;36:43-8.
115. Montine TJ, Li K, Perl DP, et al. Lack of beta-methylamino-l-alanine in brain from controls, AD, or Chamorros with PDC. Neurology. 2005;65:768-9.
116. Kisby GE, Roy DN, Spencer PS. Determination of β-N-methylamino-L- alanine (BMAA) in plant (Cycas circinalis L.) and animal tissue by precolumn derivatization with 9-fluorenylmethyl chloroformate (FMOC) and reversed-phase high-performance liquid chromatography. J Neurosci Methods. 1988;26:45-54.
117. Kushnir MM, Bergquist J. Beta-methylamino-L-alanine analysis by liquid chromatography tandem mass spectrometry with iTRAQ as the derivative. Eur J Mass Spectrom. 2009;15(3):439-43.
118. Banack SA, Cox PA, Ronnevi L-A. Unpublished observations. 2009
119. Kubo T, Kato N, Hosoya K, Kaya K. Effective determination method for a cyanobacterial neurotoxin, β-N-methylamino-L-alanine. Toxicon. 2008;51(7):1264-8.
120. Moura S, Ultramari MdA, de Paula DML, Yonamine M, Pinto E. 1H NMR determination of β-N-methylamino-l-alanine (L-BMAA) in environmental and biological samples. Toxicon. 2009;53(5):578-83.
121. Snyder LR, Cruz-Aguado R, Sadilek M, et al. Lack of cerebral BMAA in human cerebral cortex. Neurology. 2009; 72(15):1360-1.
122. Rosén J, Hellenäs KE. Determination of the neurotoxin BMAA β-N-methylamino-L-alanine) in cycad seed and cyanobacteria by LC-MS/MS (liquid chromatography tandem mass spectrometry). Analyst. 2008;133(12):1785-9.
123. Dietrich DR, Fischer A, Mchel C, Hoeger SJ. Toxin mixture in cyanobacterial blooms-a critical comparison of reality with current procedures employed in human health risk assessment. Adv Exp Med Biol. 2008;619:885-912.
124. Neurotoxin is absent from Cyanotech's spirulina. June 13, 2005 (at http://www.nutraingredients-usa.com/Industry/ Neurotoxin-is-absent-from- Cyanotech-s-spirulina, downloaded August 19, 2008).
125. Cox PA, Banack SA, Murch S, et al. (22 December 2006) Neurology http://www.neurology.org/cgi/eletters/65/5/768
126. Steele JC, McGeer PL. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology. 2008;70(21): 1984-90.
127. Borenstein AR, Mortimer JA, Schellenberg GD, Galasko D. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology 2009;72:473.
128. Bradley WG, Banack SA, Cox PA. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology. 2009; 2:474.
129. Cruz-Aguado R, Shaw CA. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology. 2009; 72:474.
130. Spencer PS, Palmer V, Kisby G. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology. 2009; 72:474-5.
131. Spina S, Murrell JR, Huey ED, Wassermann EM, Pietrini P, Grafman J, Ghetti B. Corticobasal syndrome associated with A9D progranulin mutation. J Neuropath exp Neurol. 2007;66:892-900.
132. Brouwers N, Nuytemans K, van der Zee J, Gijselinck I, et al. Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol. 2007;64:1436-46.
133. Wider C, Uitti RJ, Wszolek ZK, Fang JY et al. Progranulin gene mutation with an unusual clinical and neuropathologic presentation. Mov Disord. 2008;23(8):1168-73.
134. Ueyama H, Kumamoto T, Horinouchi H, Fujimoto S, Aono H, Tsuda T. Clinical heterogeneity in dysferlinopathy. Intern Med. 2002;41:505-6.
135. Chiba Y, Shinde A, Kohara N, Akiguchi I, Nakano S, Hayashi YK, Shibasaki H. Two sisters with dysferlinopathy manifesting different clinical phenotypes. Rinsho Shinkeigaku. 2003;43:188-91.
136. Vilchez JJ, Gallano P, Gallano E, Lasa A, et al. Identification of a novel founder mutation in the DYSF gene causing clinical variability in the Spanish population. Arch Neurol. 2005;62:1256-9.
137. Majoor-Krakauer D, Ottman R, Johnson WG, Rowland LP. Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson's disease: evidence of shared genetic susceptibility. Neurology. 1994 Oct;44(10):1872-7.
138. Fallis BA, Hardiman O. Aggregation of neurodegenerative diseases in ALS kindreds. ALS. 2009;10:95-8.
139. Seawright A, Brown AW, Nolan CC, Cavanagh JB. Selective degeneration of cerebellar cortical neurons caused by cycad neurotoxin, L-ß- methylaminoalanine (BMAA) in rats. Neuropath appl Neurobiol. 1990;16:153-169.
140. Wilson JM, Khabazian I, Wong MC, Seyedalikhani A, et al. Behavioral and neurological correlates of ALS-parkinsonism dementia complex in adult mice fed washed cycad flour. Neuromolecular Med. 2002;1(3):207-21.
141. Wilson JM, Khabazian I, Pow DV, Craig UK, et al. Decrease in glial glutamate transporter variants and excitatory amino acid receptor down-regulation in a murine model of ALS-PDC. Neuromolecular Med. 2003;3(2):105-18.
142. Wilson JM, Petrik MS, Grant SC, Blackband SJ. Examining the interaction of apo E and neurotoxicity on a murine model of ALS-PDC. Can J Physiol Pharmacol. 2005 Feb;83(2):131-41.
143. Shaw CA, Wilson JM. Analysis of neurological disease in four dimensions: insight from ALS-PDC epidemiology and animal models. Neurosci Biobehav Rev. 2003 Oct;27(6): 493-505.
144. Ly PTT, Singh S, Shaw CA. Novel environmental toxins: steryl glycosides as a potential etiological factor for age-related neurodegenerative diseases. J Neurosci Res. 2007; 85:231-37.
145. Shaw CA, Höglinger GU. Neurodegenerative diseases: neurotoxins as sufficient etiologic agents? Neuromolecular Med. 2008;10(1):1-9.
146. Tabata RC, Wilson JM, Ly P, Zwiegers P, et al. Chronic exposure to dietary sterol glucosides is neurotoxic to motor neurons and induces an ALS-PDC phenotype. Neuromolecular Med. 2008;10(1):24-39.
147. Cruz-Aguado R, Winkler D, Shaw CA. Lack of behavioral and neuropathological effects of dietary beta-methyamino-L-alanine (BMAA) in mice. Pharmacol Biochem Behav. 2006;84:294-9.
148. Khabazian I, Bains JS, Williams DE, Cheung J, et al. Isolation of various forms of sterol beta-D-glucoside from the seed of Cycas circinalis. J Neurochem. 2002;82: 516-28.
149. Schulz JD, Hawkes EL, Shaw CA. Cycad toxins, Helicobacter pylori and parkinsonism: cholesterol glucosides as the common denominator. Med Hypotheses. 2006;66(6): 1222-1226.
150. Bouic PJB, Etsebeth S, Liebenberg RW, Albrecht CF, et al. Beta-sitosterol and beta-sitosterol glucoside stimulate human peripheral blood lymphocyte proliferation. Int J Immunopharmac. 1996;18:693-7000.
151. Plant Sterols and Sterolins. Alternative Medicine Review 6.2. (April 2001):p203.
152. Sahelian R. Beta sitosterol supplement. Undated (at http://www. raysahelian.com/sitosterol.html, accessed August 19, 2008).
153. Dawson R, Marshall EG, Chan KC, Millard WJ, et al. Neurochemical and Neurobehavioral Effects of Neonatal Administration of β-N-Methylamino-L- Alanine and 3,3′-Iminodipropionitrile. Neurotox Teratol. 1998;20(2):181-192.
154. Zhou X, Papapetropoulos S, Zhai RG. L-BMAA induces neurodegeneration in Drosophila. American Academy of Neurology annual meeting. 2008;P01.110. Neurology; 70 (Suppl 1):A33.
155. Purdie EL, Samsudin S, Eddy FB, Codd GA. Effects of the cyanobacterial neurotoxin β-N-methylamino-L-alanine, on the early-life stage development of zebrafish (Danio rerio). Aquatic Toxicol. 2009; doi:10.1016/j.aquatox. 2009.02.009.
156. Scarmeas N, Shih T, Stern Y, Ottman R, Rowland LP. Premorbid weight, body mass, and varsity athletics in ALS. Neurology. 2002 Sep 10;59(5):773-5.
157. Chiò A, Traynor BJ, Swingler R, Mtchell D, et al. Amyotrophic lateral sclerosis and soccer: a different epidemiological approach strengthen the previous findings. J Neurol Sci. 2008 Jun 15;269(1-2):187-8.
158. Johnson RT, Bradley WG, Ritz B R, Rocca WA, Shefner JM, Wolfson C. Committee on the Review of the Scientific Literature on Amyotrophic Lateral Sclerosis in Veterans. Institute of Medicine. Washington, DC: National Academies of Science Press, 2006.
159. Stommel EW. ALS clusters around lakes in New Hampshire. Personal communication. 2007.
160. Banack SA, Cox PA, Murch SJ. Flying fox consumption and human neurodegenerative disease in Guam. In: Fleming T, Racey P, editors. Island Bats: Ecology Evolution, and Conervation. Chicago: The Univesity of Chicago Press, 2009 (in press).
161. Morahan JM, Yu B, Trent BJ, Pamphlett R. Genetic susceptibility to environmental toxicants in ALS. Am J Med Genet B Neuropsychiatr Genet. 2007 Oct 5;144(7):885-90.
162. Valdmanis PN, Kabashi E, Dyck A, Hince P, et al. Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec and Sweden. Neurology. 2008;71(7): 514-520.